Fecal microbiota transplantation: current clinical efficacy and future prospects.

Fecal microbiota transplantation (FMT) has gained mainstream attention with its remarkable efficacy in treating recurrent Clostridium difficile infection (RCDI) when there are no other effective therapies. Methods of selecting donors and routes of administration vary among studies, but there are now randomized controlled trials showing efficacy of FMT in treating RCDI. Ongoing trials of FMT for other disease such as inflammatory bowel disease are underway; this therapy should not be used for these conditions unless there is strong evidence for efficacy. Long-term safety data are sorely needed, as well as clarification of regulatory concerns.
AuthorsKathryn A Bowman, Elizabeth K Broussard, Christina M Surawicz
JournalClinical and experimental gastroenterology (Clin Exp Gastroenterol) Vol. 8 Pg. 285-91 ( 2015) ISSN: 1178-7023 [Electronic] New Zealand
PMID26566371 (Publication Type: Journal Article, Review)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: